|
|
|
|
|
by pizzathyme
229 days ago
|
|
I can understand the current global/political environment against mRNA accounting for a 90% fall in revenues and valuation. But if the mRNA tech is still progressing and promising for a variety of ailments like cancer, then the company still has substantial future value coming |
|
The technology they invented is incredibly promising for new vaccines and they should be attracting enough investment (through contracts or other deals) to continue innovating and saving lives. Maybe they can license it as a last ditch effort to build revenue, but unfortunately the public perceptions about vaccine efficacy is on the wane and government contracts are no longer there to support this vital work both in the present and as a hedge against future pandemics.